Current Concepts in Antifungal Pharmacology

August 2011
Mayo Clinic Proceedings;Aug2011, Vol. 86 Issue 8, p805
Academic Journal
The introduction of new antifungal agents (eg, echinocandins, second-generation triazoles) in the past decade has transformed the management of invasive mycoses to the point that drug toxicity is no longer the major limiting factor in treatment. Yet, many of these newer antifungal agents have important limitations in their spectrum of activity, pharmacokinetics, and unique predisposition for pharmacokinetic drug-drug interactions and unusual toxicities associated with long-term use. This article reviews key pharmacological aspects of systemic antifungal agents as well as evolving strategies, such as pharmacokinetic-pharmacodynamic optimization and therapeutic drug monitoring, to improve the safety and efficacy of systemic antifungal therapy.


Related Articles

  • Caspofungin. PARAKH, ANKIT; DUBEY, ANAND PRAKASH; SAMANTA, DEBOPAM // Indian Pediatrics;Nov2008, Vol. 45 Issue 11, p905 

    Caspofungin is a new antifungal drug meant for intravenous use. It has been shown to be comparable to other antifungal agents such as amphotericin B and fluconazole for empirical therapy in febrile neutropenic patients, oropharyngeal/esophageal candidiasis and invasive aspergillosis. Its...

  • Conclusions. de Bellis, Pasquale // Drugs;2009 Supplement, Vol. 69, p99 

    Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. Anidulafungin is a well tolerated echinocandin with a favorable pharmacokinetic profile; in particular, its lack of hepatic metabolism and renal excretion enables drug administration...

  • Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Morris, Michele I. // American Journal of Health-System Pharmacy;2/1/2009, Vol. 66 Issue 3, p225 

    The article examines the pharmacology, pharmacokinetics, pharmacodynamics, spectrum of activity and resistance, clinical utility, adverse effects, dosage and administration and recommended monitoring of posaconazole. It describes posaconazole as a member of the azole class of antifungals...

  • VASCULAR HEADACHE SUPPRESSANTS.  // Davis's Drug Guide for Nurses, 9th edition;2005, pC76 

    Presents pharmacologic information on vascular headache suppressants. Pharmacokinetics; Drug interactions; Evaluation of effectiveness.

  • Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Venkatakrishnan, K.; von Moltke, L.L.; Greenblatt, D.J. // Clinical Pharmacokinetics;2000, Vol. 38 Issue 2, p111 

    This article reviews the metabolic pharmacokinetic drug-drug interactions with the systemic antifungal agents: the azoles ketoconazole, miconazole, itraconazole and fluconazole, the allylamine terbinafine and the sulfonamide sulfamethoxazole. The majority of these interactions are metabolic and...

  • Fungal Infections: Their Diagnosis and Treatment in Transplant Recipients. Van Thiel, David H.; George, Magdalena; Moore, Christopher M. // International Journal of Hepatology;2012, p1 

    Systemic fungal infections typically occur in individuals who are seriously ill with recognized risk factors such as those frequently found in transplant recipients. Unfortunately, they are often diagnosed late, when the efficacy of the available treatments is low, often less than 50%, and the...

  • Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy. Boucher, Helen W.; Gross, Andreas H.; Chiou, Christine C.; Walsh, Thomas J. // Drugs;2004, Vol. 64 Issue 18, p1997 

    The past few years have seen the advent of several new antifungal agents, including those of a new class and a new generation of an existing class. Caspofungin, the first available echinocandin, has greatly expanded the antifungal armamentarium by providing a cell wall-active agent with...

  • Humanized Transgenic Mouse Models for Drug Metabolism and Pharmacokinetic Research. Hong-Wu Shen; Xi-Ling Jiang; Gonzalez, Frank J.; Ai-Ming Yu // Current Drug Metabolism;Dec2011, Vol. 12 Issue 10, p997 

    Extrapolation of the metabolic, pharmacokinetic and toxicological data obtained from animals to humans is not always straightforward, given the remarkable species difference in drug metabolism that is due in large part to the differences in drugmetabolizing enzymes between animals and humans....

  • ANTIPLATELET AGENTS.  // Davis's Drug Guide for Nurses, 9th edition;2005, pC32 

    Presents pharmacologic information on antiplatelet agents. Pharmacokinetics; Side effects; Drug interactions.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics